The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro

Ancrenaz, Virginie; Desmeules, Jules Alexandre; James, Richard William; Fontana, Pierre; Reny, Jean-Luc; Dayer, Pierre; Daali, Youssef

doi:10.1111/j.1476-5381.2012.01946.x

Scientific article

English

The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro

ContributorsAncrenaz, Virginie; Desmeules, Jules Alexandre; James, Richard William; Fontana, Pierre; Reny, Jean-Luc

; Dayer, Pierre; Daali, Youssef

Published inBritish journal of pharmacology, vol. 166, no. 8, p. 2362-2370

Publication date2012

Abstract

Clopidogrel is a prodrug bioactivated by cytochrome P450s (CYPs). More recently, paraoxonase-1 (PON1) has been proposed as a major contributor to clopidogrel metabolism. The purpose of this study was to assess the relative contribution of CYPs and PON1 to clopidogrel metabolism in vitro.

Affiliation entities

Research groups

Citation (ISO format)

ANCRENAZ, Virginie et al. The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. In: British journal of pharmacology, 2012, vol. 166, n° 8, p. 2362–2370. doi: 10.1111/j.1476-5381.2012.01946.x

Article (Published version)

Identifiers

PID : unige:26343
DOI : 10.1111/j.1476-5381.2012.01946.x
PMID : 22428615

Journal ISSN0007-1188

594views

0downloads

Creation08/11/2012 14:22:00

First validation08/11/2012 14:22:00

Update03/02/2025 11:35:25

Status update03/02/2025 11:35:25

Last indexation03/02/2025 11:41:23

Archive ouverte UNIGE

The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro

Clopidogrel is a prodrug bioactivated by cytochrome P450s (CYPs). More recently, paraoxonase-1 (PON1) has been proposed as a major contributor to clopidogrel metabolism. The purpose of this study was to assess the relative contribution of CYPs and PON1 to clopidogrel metabolism in vitro.

Technical informations